RECRUITING

Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes

Description

Prediabetes effects 96 million people 18 years of age or older. It is important to identify treatment options to slow or prevent progression to diabetes. It is also critical to assess the potential of medications like sodium glucose transporter 2 inhibitors to reduce the risk of cardiovascular events and kidney complications, both common and costly complications of diabetes. This is a 12-week, open-label pilot feasibility study assessing the use of empagliflozin in prediabetes.

Conditions

Prediabetes
Talk to us

Related Conditions:

Prediabetes

Study Overview

On this page

Study Details

Study overview

Prediabetes effects 96 million people 18 years of age or older. It is important to identify treatment options to slow or prevent progression to diabetes. It is also critical to assess the potential of medications like sodium glucose transporter 2 inhibitors to reduce the risk of cardiovascular events and kidney complications, both common and costly complications of diabetes. This is a 12-week, open-label pilot feasibility study assessing the use of empagliflozin in prediabetes.

Sodium-glucose Transporter 2 Inhibitor Use in Pre-diabetes: Initial Evaluation in Veterans

Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes

Condition
Prediabetes
Intervention / Treatment

-

Contacts and Locations

Asheville

Charles George VA Medical Center, Asheville, North Carolina, United States, 28805

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 35 to 60 years at time of enrollment
  • * Able to read and speak English
  • * Diagnosis of diabetes (type 2 or type 1)
  • * Contraindication to SGLT2i medication per medication labeling, prior adverse reaction to SGLT2i medication, or received SGLT2i medication within the 6 months prior to enrollment
  • * Currently prescribed an antihyperglycemic agent approved for treatment of type 2 diabetes or taking any FDA-approved weight loss agent or over-the-counter supplement promoted for weight loss
  • * Veterans unable to complete informed consent process (Veterans with impaired decision-making ability or who require use of a legally authorized representative)
  • * Women who are pregnant or may become pregnant
  • * Veterans with neurogenic bladder, indwelling catheter, or urinary tract infection within the previous 12 months requiring hospitalization or emergency department visit

Ages Eligible for Study

35 Years to 60 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Charles George VA Medical Center,

Study Record Dates

2026-06